|
|
|
| Preparation of braining-targeting liposomes and the structural stability of Ac4MAN on the surface of liposome in vitro |
| LI Rubing1 WANG Na2 LIU Xiaoying2 TANG Shukun2 PENG Haisheng1,2 TAO Haiquan3 |
1.Research Center of Life Sciences and Environmental Sciences, Harbin University of Commerce, Heilongjiang Province, Harbin 150028, China;
2.Department of Pharmaceutics, Campus of Harbin Medical University(Daqing), Heilongjiang Province, Daqing 163319, China;
3.Department of Neurosurgery, the 2nd Affiliated Hospital of Harbin Medical Hospital, Heilongjiang Province, Harbin 150000, China |
|
|
|
Abstract Objective To construct a modified Ac4MAN (p-carboxybenzene-α-D-acetylmannose) brain-targeted liposome and investigate the structural stability of Ac4MAN. Methods Ac4MAN was incubated with porcine liver esterase (PLE) at 37°C, pH 7.4 and sampled at different time points. High performance liquid chromatography (HPLC) and ultra performance liquid chromatography-mass spectrometry (UPLC-MS) were used to analyze it. Ac4MAN liposomes were prepared and characterized. Flow cytometry was used to detect the uptake of Ac4MAN liposomes and Ac4MAN liposomes plus PLE by glioma cells U87. Results The results of HPLC showed that the area of Ac4MAN decreased from 578.4 to 37.9 after incubation for 0-3 h. The area of Ac4MAN peak was close to 0 after incubation for 4-7 h. The peak area of the formed MAN (p-aminobenzene-α-D-pyran mannoside) increased from 0 to 363.0, indicating that with the prolongation of incubation time, Ac4MAN gradually decreased and MAN gradually increased. Conclusion The Ac4MAN liposome prepared in this study has a particle size of (120.3±2.0) nm and a potential of (-15.76±1.23) mV. The uptake of AC4MAN liposomes by U87 cells is enhanced after adding enzymes.
|
|
|
|
|
|
[1] Jahan ST，Sadat SMA，Walliser M，et al. Targeted therapeutic nanoparticles：An immense promise to fight against cancer [J]. J Drug Deliv，2017：9 090 325.
[2] Castro MG，Candolfi M，Kroeger K，et al. Gene therapy and targeted toxins for glioma [J]. Curr Gene Ther，2011，11（3）：155-180.
[3] Shukla GH，Kour Khera A，Kumar S，et al. Therapeutic potential， challenges and future perspective of cancer stem cells in translational oncology：a critical review [J]. Curr Stem Cell Rest，2017，12（3）：207-224.
[4] Bar-Zeev M，Livney YD，Assaraf YG. Targeted nanomedicine for cancer therapeutics： Towards precision medicine overcoming drug resistance [J]. Drug Resist Update，2017，31：15-30.
[5] Mujokoro B，Adabi M，Sadroddiny E，et al. Nano-structures mediated co-delivery of therapeutic agents for glioblastoma treatment：A review [J]. Mater Sci Eng C Mater Biol Appl，2016，69：1092-1102.
[6] Riaz MK，Riaz MA，Zhang X，et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy：A revie [J]. Int J Mol Sci，2018，19（1）：195-212.
[7] Pinto MP，Arce M，Yameen B，et al. Targeted brain delivery nanoparticles for malignant gliomas [J]. Nanomedicine （Lond），2017，12（1）：59-72.
[8] Maherani BE，Arab-Tehrany M， Mozafari R，et al. Liposomes： a review of manufacturing techniques and targeting strategies [J]. Curr Nano Sci，2011，7（3）：436-452.
[9] Siafaka PI，Ustundag Okur N，Karavas E，et al. Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting：current status and uses [J]. Int J Mol Sci，2016，17（9）：1440.
[10] Szablewski L. Glucose Transporters in Brain： In Health and in Alzheimer′s Disease [J]. J Alzheimers Dis，2017， 55（4）：1307-1320.
[11] Hao ZF，Cui YX，Li MH，et al. Liposomes modified with P-aminophenyl-alpha-D-manno-pyranoside： a carrier for targeting cerebral functional regions in mice [J]. Eur J Pharm Biopharm，2013，84（3）：505-516.
[12] Nishioka T，Oda Y，Seino Y，et al. Distribution of the glucose transporters in human brain tumors [J]. Cancer Res，1992，52（14）：3972-3979.
[13] Du D，Chang N，Sun S，et al. The role of glucose transporters in the distribution of p-aminophenyl-alpha-D-mannopyranoside modified liposomes within mice brain [J]. J Control Release，2014，182：99-110.
[14] Miranda A，Blanco-Prieto MJ，Sousa J，et al. Breaching barriers in glioblastoma. Part Ⅱ： Targeted drug delivery and lipid nanoparticles [J]. Int J Pharm，2017，531（1）：389-410.
[15] Woodle MC，Newman MS，Working PK. Biological properties of sterically stabilized liposomes，in Stealth liposomes [J]. CRC Press，2018：123-138.
[16] Pradhan P，Banerjee R，Bahadur D，et al. Targeted Magnetic Liposomes Loaded with Doxorubicin，in Liposomes [J]. Springer，2017：257-272.
[17] Weissig V. Liposomes came first：The early history of liposomology，in Liposomes [J]. Springer，2017：1-15.
[18] Bnyan R，Khan I，Ehtezazi T，et al. Surfactant Effects on Lipid-Based Vesicles Properties [J]. J Pharm Sci，2018， 107（5）：1237-1246.
[19] Mu LM，Ju RJ，Liu R，et al. Dual-functional drug liposomes in treatment of resistant cancers [J]. Adv Drug Deliver Rev，2017，115：46-56.
[20] Jurcovicova J. Glucose transport in brain-effect of inflammation [J]. Endocr Regul，2014，48（1）：35-48. |
|
|
|
